Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

March 17, 2011 13:27 ET

Ambrilia Biopharma Announces Approval of Licensing of MTX and OSK-1 And of An Option Agreement For PSP-94

MONTREAL, QUEBEC--(Marketwire - March 17, 2011) - Ambrilia announces that it has entered into a Heads of Agreement with ZBx Corporation (''Option''), granting ZBx an option to acquire irrevocable and exclusive worldwide rights to Ambrilia's proprietary PSP-94 reagents and related intellectual property (''PSP-94''). ZBx can exercise its option during a period which starts 90 days from, and expires 120 days after, the effective date of the Option. If ZBx exercises such option, Ambrilia would be eligible to receive up to a total of $50,000 upon signing of a definitive agreement and achievement of sales milestones, as well as royalties on sales and a percentage share of proceeds from any sublicenses or sale of PSP-94 by ZBx. ZBx will cover all future costs associated with the further development, manufacturing and commercialization of PSP-94. The Option was approved and authorized by the Commercial Chamber of the Superior Court of Montreal pursuant to an Order rendered today. 

Ambrilia also announced that its previously-announced worldwide licensing agreement with Tournoux Biotech SAS of France for the development, manufacture and sale of its MTX and OSK1 technologies, under the terms of which, Ambrilia could receive future milestone and royalty payments, was also approved and authorized by the Commercial Chamber of the Superior Court of Montreal pursuant to an Order rendered today. 

Ambrilia has been operating under the protection of the Companies' Creditors Arrangement Act (Canada) ("CCAA") since July 31, 2009.

Any recovery for creditors and other stakeholders, including shareholders, is uncertain and is highly dependent upon a number of factors, including the outcome of Ambrilia proceedings under the CCAA.

About Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc. is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. Ambrilia's head office is located in Montreal. For more information, please visit the Company's web site: www.ambrilia.com.

The Company is currently subject to court protection under the CCAA.

Ambrilia's forward looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, the timing and continuance of the CCAA protection, the uncertainty involved in the court proceedings and the implementation of any plan of arrangement under the CCAA, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's annual information form which contains a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful emergence from the insolvency proceedings, the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. Failure to complete a strategic or financial transaction as a result of the review of strategic alternatives could have a material adverse effect on Ambrilia. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.

Contact Information